EGFR and myocardial infarction: In line with other studies’ results (Li et al. 2022a, b; Sun et al. 2022; Liang et al. 2023), EGFR, HSP90AA1 and SRC were also recognized as key targets for treating atherosclerosis or acute myocardial infarction through network pharmacology and molecular docking.